Functional Evaluation Of The autonomic nervous system in the context of the first intake of 0.5 mg of fingolimod (Gilenya) in patients with relapsing-leveling multiple sclerosis

Trial Profile

Functional Evaluation Of The autonomic nervous system in the context of the first intake of 0.5 mg of fingolimod (Gilenya) in patients with relapsing-leveling multiple sclerosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 May 2016

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Autonomic-nervous-system-disorders; Multiple sclerosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 28 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Feb 2015 Planned End Date changed from 1 Aug 2014 to 1 Jun 2015, as reported by ClinicalTrials.gov.
    • 02 Feb 2015 Planned primary completion date changed from 1 Aug 2014 to 1 Jun 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top